ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

Share

Clinical Report: Silevertinib in Lung Cancer

Overview

Dr. Julia Rotow presented data on silevertinib in the context of EGFR non-small cell lung cancer variants.

Background

The treatment landscape for EGFR-mutated non-small cell lung cancer (NSCLC) is evolving, with new therapies emerging for both common and uncommon mutations. Silevertinib is being studied as a potential treatment option.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

  • Silevertinib is being investigated for its efficacy in treating EGFR NSCLC variants.
  • Side effects associated with silevertinib were reported as manageable.
  • Current standards for common EGFR mutations include osimertinib with chemotherapy.
  • Uncommon EGFR mutations still require mutation-directed approaches for optimal treatment.

Clinical Implications

Further research is necessary to define the role of silevertinib in the treatment of EGFR mutations.

Conclusion

Further investigation into silevertinib's role in treating specific EGFR non-small cell lung cancer variants is needed.

Related Resources & Content

  1. Dana-Farber, ASCO26: Julia Rotow, MD. — NSCLC Study Presented by Julia Rotow, MD.
  2. FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer | FDA
  3. From Rarity to Reality: Osimertinib’s Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer | Clinical Cancer Research | American Association for Cancer Research
  4. dana-farber — ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
  5. dana-farber — ASCO26: Sara Tolaney, MD, MPH, ASCENT-04
  6. The ASCO Post — Expert Point of View: Christine Lovly, MD, PhD
  7. FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer | FDA
  8. From Rarity to Reality: Osimertinib’s Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer | Clinical Cancer Research | American Association for Cancer Research
  9. Definition of silevertinib - NCI Drug Dictionary - NCI

Original Source(s)

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

  • July 1, 2026

Related Content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers

The evolution of RTOG and NRG Oncology CNS tumors clinical trials